West Pharmaceutical Services, Inc. WST

West Pharmaceutical Services (WST) could see earnings per share upside of at least 10% to current Wa

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

West Pharmaceutical Services recently announced it will phase out a product line at its Scottsdale facility by the end of September, resulting in 98 layoffs. At the same time, the company’s push into higher-value products and Annex 1-related sterility upgrades is being tempered by cyber incident disruptions in its West Vantage segment and tariff- and commodity-driven cost pressures. We’ll now examine...

West Pharmaceutical Services (WST) is juggling mixed signals after recent updates on its business outlook. Investors now have to balance long-term growth drivers with fresh headwinds from a cyber incident, cost inflation, and a Scottsdale product line shutdown. Recent price action reflects that push and pull. The share price is up 9.89% over the past 90 days and 31.08% year to date, while the 1-year total shareholder return of 42.61% contrasts with a slightly negative 3-year total shareholder...

West Pharmaceutical Services has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.